While Roivant Sciences (ROIV) has been seeing stable revenue growth, its bottom line is in the red. So, will it be worth owning ROIV now? Let’s discuss some of its key financial metrics to gauge its...
The market's dour reaction to Roivant Sciences' latest deal doesn't add up.
These three top mid-cap stocks could be poised for a long-tailed growth spurt.
The company may have best-in-class autoimmune disease therapy under its roof.
Immunovant sees strong potential for an autoimmune disorder therapy.
Stock index futures pointed to a lower open on Wall Street Tuesday morning.
A top hedge fund has been steadily buying these two growth stocks in 2023.
Housing, Retail Figures Due Next Week Monday U.S. Featured Earnings Roivant (NASDAQ: ...
These biotech stocks could markedly outperform the broader market.